The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.
Philippa Corrie
No relevant relationships to disclose
Martyn Caplin
No relevant relationships to disclose
Nicholas Reed
No relevant relationships to disclose
Wendi Qian
No relevant relationships to disclose
Si-houy Lao-Sirieix
No relevant relationships to disclose
Richard Hardy
No relevant relationships to disclose
Graham Armstrong
No relevant relationships to disclose
Juan W. Valle
No relevant relationships to disclose
Denis Charles Talbot
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; AstraZeneca; Roche
Expert Testimony - Amgen (U)
Tu Vinh Luong
No relevant relationships to disclose
Ashley Shaw
No relevant relationships to disclose
Tim Meyer
No relevant relationships to disclose